Erlotinib hydrochloride
SIGMA/SML2156 - ≥98% (HPLC)
Synonym: 774 hydrochloride; CP-358; N-
CAS Number: 183319-69-9
Empirical Formula (Hill Notation): C22H23N3O4 · HCl
Molecular Weight: 429.90
MDL Number: MFCD07781272
Linear Formula: C22H23N3O4 · HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C22H23N3O4.ClH/c1-4-16 |
| InChI key | GTTBEUCJPZQMDZ-UHFFFAOYSA |
| SMILES string | Cl.N(c3cc(ccc3)C#C)c1ncnc |
| solubility | DMSO: 2 mg/mL, clear (warmed) |
| storage condition | desiccated |
| storage temp. | −20°C |
| Application: | Erlotinib hydrochloride has been used to activate mitochondrial fragmentation in a human PANC-1 pancreatic cancer cell line. |
| Biochem/physiol Actions: | EGFR kinase inhibitor; Antineoplastic |
| Biochem/physiol Actions: | Erlotinib hydrochloride is an inhibitor of the receptor tyrosine kinase EGFR (epidermal growth factor receptor). It is used clinically for the treatment of non-small cell lung cancer (NSCLC) and in combination for metastatic pancreatic cancer. |
| General description: | Erlotinib hydrochloride is an antineoplastic drug. It regulates mechanistic target of rapamycin (mTOR) inhibition, epidermal growth factor receptor down-regulation and epidermal interstitial transformation (EMT) suppression. |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264 - P270 - P301 + P312 - P501 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |

